Results 41 to 50 of about 1,022 (137)
A randomized, placebo-controlled experimental medicine study of RIPK1 inhibitor GSK2982772 in patients with moderate to severe rheumatoid arthritis. [PDF]
, 2021 Funder: GlaxoSmithKline; doi: http://dx.doi.org/10.13039/100004330BACKGROUND: Receptor-interacting protein kinase 1 (RIPK1) is a key mediator of inflammation through cell death and proinflammatory cytokine production. This multicenter, randomized, double-Berger, Scott, Burriss, Susan W, Peterfy, Charles, Quattrocchi, Emilia, Siddall, Hilary, Tak, Paul Peter, Taylor, Peter C, Thorn, Katie, Tompson, Debra, Walter, Jochen, Wang, Susanne, Weisel, Kathleen +11 morecore +1 more sourceIntent to Treat Analysis of the Primary and Secondary Outcomes for the ODINN Intact Fish Skin Graft for Deep Diabetic Foot Wounds Trial
International Wound Journal, Volume 23, Issue 3, March 2026.ABSTRACT
There is a significant need for trials that evaluate the treatment of University of Texas (UT) grade 2 and 3 diabetic foot ulcers (bone, joint, or tendon exposed wounds). We undertook a trial looking at the effect of intact fish skin graft (IFSG) on these deep and difficult‐to‐heal ulcers.Dured Dardari, Alberto Piaggesi, Louis Potier, Ariane Sultan, Holger Diener, Maud Francois, Bernhard Dorweiler, Benjamin Bouillet, Jocelyne M'Bemba, Lucy Chaillous, Giacomo Clerici, Laurence Kessler, Walter Wetzel‐Roth, Martin Storck, Dereck Shi, Olafur Davidsson, Baldur Baldursson, Hilmar Kjartansson, Guillaume Charpentier, John C. Lantis II +19 morewiley +1 more sourceMusculoskeletal Diseases: Mechanisms and Therapeutic Advances
MedComm, Volume 6, Issue 12, December 2025.Musculoskeletal diseases comprise a broad spectrum of inflammatory, degenerative, and neoplastic disorders. Increasing evidence highlights the central role of immune regulation in their pathogenesis, with complex interactions among immune, bone, muscle, and stromal cells.Xiao Ma, Eloy Yinwang, Xupeng Chai, Fangqian Wang, Zehao Chen, Shengdong Wang, Hao Zhou, Yucheng Xue, Jiangchu Lei, Fanglu Chen, Hengyuan Li, Shixin Chen, Shenzhi Zhao, Kelei Wang, Liang Chen, Junjie Gao, Zhaoming Ye, Nong Lin +17 morewiley +1 more sourceSubclinical joint inflammation in patients with psoriasis without concomitant psoriatic arthritis: a cross-sectional and longitudinal analysis [PDF]
, 2018 Objectives To search for subclinical inflammatory joint disease in patients with psoriasis without psoriatic arthritis (PsA), and to determine whether such changes are associated with the later development of PsA.Cavallaro, Alexander, Englbrecht, Matthias, Faustini, Francesca, Figueiredo, Camille, Haschka, Judith, Hueber, Axel J., Kleyer, Arnd, Kocijan, Roland, Kraus, Sebastian, Oliveira, Isabelle, Ponte Tabosa, Taiane, Rech, Jürgen, Rodrigues Cavalcante, Alan, Schett, Georg, Simon, David, Sticherling, Michael +15 morecore +2 more sourcesAntimicrobial prescribing guidelines for horses in Australia
Australian Veterinary Journal, Volume 103, Issue 12, Page 781-889, December 2025.The growing problem of antimicrobial resistance also affects equine veterinarians with increasing frequency. Antimicrobial stewardship and responsible prescribing are essential for a future in which effective antimicrobials are available, as it is unlikely that new antimicrobials will become available for use in horses.L Hardefeldt, K Thomas, S Page, J Norris, G Browning, C El Hage, A Stewart, J Gilkerson, G Muscatello, D Verwilghen, G van Galen, J Bauquier, R Cuming, B Reynolds, C Whittaker, E Wilkes, J Clulow, C Burden, L Begg +18 morewiley +1 more sourceAdalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation. [PDF]
, 2016 OBJECTIVES: Rheumatoid arthritis (RA) is a chronic inflammatory disease associated with increasing disability, reduced quality of life and substantial costs (as a result of both intervention acquisition and hospitalisation).Abe, Akaike, Alamanos, Aletaha, Allaart, Allaire, Anderson, Arnett, AstraZeneca, Bae, Bansback, Bansback, Bansback, Bansback, Barbieri, Barton, Bathon, Bathon, Bejarano, Bejarano, Benucci, Blumenauer, Blumenauer, Boggs, Boini, Bollen, Bradford Teaching Hospitals NHS Trust, Brazier, Breedveld, Brennan, Brennan, Bristol-Myers Squibb, Bruce, Burmester, Centre for Reviews and Dissemination, Chakravarty, Chen, Chiou, Choi, Combe, Combe, Combe, Conaghan, Conaghan, Conner-Spady, Connock, Coyle, Curtis, Curtis, Curtis, Dadoun, Davies, deFilippis, Deighton, Department of Health, Department of Health, Department of Health, Department of Health, Detert, Diamantopoulos, Dias, Dixon, Dolan, Dougados, Drossaers-Bakker, Drummond, Drummond, Du Pan, Ducournau, Durez, Durez, Eddy, Edwards, Electronic Medicines Compendium, Electronic Medicines Compendium, Electronic Medicines Compendium, Electronic Medicines Compendium, Electronic Medicines Compendium, Electronic Medicines Compendium, Electronic Medicines Compendium, Electronic Medicines Compendium, Emery, Emery, Emery, Emery, Emery, Emery, Felson, Felson, Finckh, Fleischmann, Fleischmann, Fleischmann, Fleischmann, Furst, Gabay, Gabay, Gabriel, Galloway, Genovese, Genovese, Genovese, Genovese, Goekoop-Ruiterman, Golder, Graudal, Grigor, Guyot, Harland, Haugeberg, Hawthorne, Haynes, Heijde, Hernandez-Alava, Hernandez-Alava, Hernandez-Alava, Hetland, Hidaka, Higgins, Hjardem, Hoyle, Hurst, Hyrich, Hørslev-Petersen, Information Services, Canadian Agency for Drugs and Technologies in Health (CADTH), Jobanputra, Jobanputra, Jobanputra, Joint Formulary Committee, Joint Formulary Committee, Joint Formulary Committee, Jones, Jones, Kameda, Kameda, Kameda, Kang, Karsh, Kavanaugh, Kay, Kekow, Keystone, Keystone, Keystone, Keystone, Keystone, Keystone, Kim, Kim, Klareskog, Kobelt, Kobelt, Kobelt, Kobelt, Kobelt, Kobelt, Kobelt, Kosinski, Kremer, Kremer, Kremer, Kremer, Kremer, Kremer, Kremer, Kremer, Kremer, Kume, Lan, Lefebvre, Lekander, Lindgren, Lipsky, Lugmani, Maetzel, Maini, Maini, Malottki, Marra, Marra, Mathias, Mcinnes, McWilliams, Merkesdal, Meune, Michaud, Miyasaka, Montori, Moreland, Moreland, Multiple Technology Appraisal, Munro, Nam, National Collaborating Centre for Chronic Conditions, National Collaborating Centre for Chronic Conditions (UK), National Institute for Health and Care Excellence, National Institute for Health and Care Excellence, National Institute for Health and Care Excellence, National Institute for Health and Care Excellence, National Institute for Health and Care Excellence, National Institute for Health and Care Excellence, National Institute for Health and Care Excellence, National Institute for Health and Care Excellence, National Institute for Health and Care Excellence, National Institute for Health and Care Excellence, National Institute for Health and Care Excellence, National Institute for Health and Care Excellence, National Institute for Health and Care Excellence, National Institute for Health and Care Excellence, National Institute for Health and Care Excellence, National Institute for Health and Care Excellence, National Institute for Health and Care Excellence, National Institute for Health and Care Excellence, National Institute for Health and Care Excellence, National Institute for Health and Care Excellence, National Institute for Health and Care Excellence, Navarro-Sarabia, Naz, NHS, Nishimoto, Nishimoto, Nishimoto, Nishimoto, Nishimoto, Norton, Norton, Norton, Nuijten, Office for National Statistics, Office for National Statistics, Oppong, Ostergaard, O’Dell, O’Dell, O’Hagan, Pincus, Pincus, Pincus, Plant, Prevoo, Quinn, Roche, Rubio-Terrés, Ruiz Garcia, Russell, Russell, Satorra, Schering-Plough Ltd, Schiff, School of Health and Related Research, University of Sheffield, Scott, Scott, Scott, Singh, Singh, Singh, Singh, Singh, Smolen, Smolen, Smolen, Smolen, Smolen, Smolen, Smolen, Soini, Soliman, Soubrier, Spalding, St Clair, Strand, Strand, Symmons, Symmons, Symmons, Tanaka, Tanno, Thorlund, Tierney, Trueman, UCB Pharma, Van De Putte, van den Hout, van der Heide, van der Heijde, van der Heijde, van der Kooij, van Gestel, van Gestel, van Riel, van Riel, van Vollenhoven, van Vollenhoven, van Vollenhoven, van Vollenhoven, Vera-Llonch, Wailoo, Weinblatt, Weinblatt, Weinblatt, Weinblatt, Weinblatt, Weinblatt, Welsing, Westhovens, Wilczynski, Wiles, Wolfe, Wolfe, Wong, Wong, Wong, Wong, Wu, Yelin, Young, Zhang, Zink +317 morecore +2 more sourcesCardiovascular Morbidity in Patients Undergoing Successful Surgery for Primary Hyperparathyroidism
Clinical Endocrinology, Volume 103, Issue 5, Page 669-681, November 2025.ABSTRACT Objective
Although previous studies have shown reduced cardiovascular events following parathyroidectomy (PTX), it is unclear whether this extends to contemporary patients diagnosed and treated with milder disease than previously. The aim of this nation‐wide study was to determine the effect on cardiovascular events after PTX, and to ...Martin Nilsson, J. Gustav Smith, Mark Thier, Erik Nordenström, Anders Bergenfelz, Martin Almquist +5 morewiley +1 more sourceJAK Inhibitors for Treatment of SAPHO Syndrome: A Systematic Review of 72 Cases
ACR Open Rheumatology, Volume 7, Issue 10, October 2025.Objective
Synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome usually involves bones, joints, and skin. Due to a lack of known pathogenesis and clinical trials, there is no standard treatment of SAPHO syndrome. Because none of the current treatments have a high efficacy and the risk of relapse is high, new treatment options for ...Patrick Fazeli, Saeed Bahramian, Kimia Farahmand, Hamed Ghoshouni, Yalda Farahmand, Amirali Soheili, Leyla Bagheri, Huria Memari, Aydin Feyzi, Seyed Mohammad Vahabi +9 morewiley +1 more source
